Exelixis Files Patent Complaint Against Cipla's Cancer Treatment
By Sabela Ojea
Exelixis has filed a complaint for an alleged patent infringement against Cipla and its abbreviated new drug application that is now pending with the Food and Drug Administration.
The company said on Friday that it's seeking an order to make the effective date of any FDA approval of Cipla's abbreviated new drug application after the expiration of a number of its patents, the latest of which expires on Feb. 10, 2032.
Exelixis is also requesting and equitable relief enjoining Cipla from infringing its patents, the company said.
Cipla's abbreviated new drug application now requests approval to market generic versions of its anti-cancer treatment Cabometyx in tablets with 20 milligrams and 40 milligrams dosage strengths prior to the expiration of some patents.
The company on Thursday filed the complaint in the U.S. District Court for the District of Delaware.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 10, 2024 17:18 ET (21:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but There’s a Catch
-
Lululemon Earnings: On Track to Meet Expectations Despite Slowdown In Americas
-
What Is Driving Small-Cap Stock Underperformance?
-
After Earnings, Is Zscaler Stock a Buy, a Sell, or Fairly Valued?
-
ASML Fair Value Raised as Outlook Improves